APC/C dysfunction limits excessive cancer chromosomal instability

Cancer Discovery

Volumn 7, Issue 2, 2017, Pages 218-233

  Sansregret, Laurent ^a   Patterson, James O ^a   Dewhurst, Sally ^a   López García, Carlos ^a   Koch, André ^b   McGranahan, Nicholas ^a,c   Chao, William Chong Hang ^a   Barry, David J ^a   Rowan, Andrew ^a   Instrell, Rachael ^a   Horswell, Stuart ^a   Way, Michael ^a   Howell, Michael ^a   Singleton, Martin R ^a   Medema, René H ^b   Nurse, Paul ^a   Petronczki, Mark ^a,d   Swanton, Charles ^a,c  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c University of Manchester and University College London   (Austria)

^d BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHASE PROMOTING COMPLEX; SMALL INTERFERING RNA; ANAPHASE PROMOTING COMPLEX SUBUNIT 3; CDC27 PROTEIN, HUMAN;

ANEUPLOIDY; ARTICLE; CDC27 GENE; CELL HETEROGENEITY; CELL VIABILITY; CHROMOSOMAL INSTABILITY; CHROMOSOME SEGREGATION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; FISH; GENE; GENE DUPLICATION; GENE MUTATION; GENE SEQUENCE; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; M PHASE CELL CYCLE CHECKPOINT; MISSENSE MUTATION; MITOSIS; NEOPLASM; NONHUMAN; POMBE STRAIN HANDLING; PROCEDURES; TIME LAPSE IMAGING; CRISPR CAS SYSTEM; GENE EDITING; GENETICS; GENOMICS; HCT 116 CELL LINE; HT-29 CELL LINE; METABOLISM; TUMOR CELL LINE;

ANAPHASE-PROMOTING COMPLEX-CYCLOSOME; APC3 SUBUNIT, ANAPHASE-PROMOTING COMPLEX-CYCLOSOME; CELL LINE, TUMOR; CHROMOSOMAL INSTABILITY; CRISPR-CAS SYSTEMS; GENE EDITING; GENOMICS; HCT116 CELLS; HT29 CELLS; HUMANS; MITOSIS; NEOPLASMS;

EID: 85011883158     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0645     Document Type: Article

References (78)

1. Santaguida S, Amon A. Short-and long-term effects of chromosome missegregation and aneuploidy. Nat Rev Mol Cell Biol 2015; 16: 473-85.
2. Thompson SL, Compton DA. Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J Cell Biol 2010; 188: 369-81.
3. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 2005; 437: 1043-7.
4. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009; 460: 278-82.
5. Selmecki A, Forche A, Berman J. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 2006; 313: 367-70.
6. Chen G, Mulla WA, Kucharavy A, Tsai HJ, Rubinstein B, Conkright J, et al. Targeting the adaptability of heterogeneous aneuploids. Cell 2015; 160: 771-84.
7. Chen G, Bradford WD, Seidel CW, Li R. Hsp90 stress potentiates rapid cellular adaptation through induction of aneuploidy. Nature 2012; 482: 246-50.
8. Pavelka N, Rancati G, Zhu J, Bradford WD, Saraf A, Florens L, et al. Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast. Nature 2010; 468: 321-5.
9. Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 2011; 71: 1858-70.
10. Sotillo R, Schvartzman JM, Socci ND, Benezra R. Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature 2010; 464: 436-40.
11. Li R, Hehlman R, Sachs R, Duesberg P. Chromosomal alterations cause the high rates and wide ranges of drug resistance in cancer cells. Cancer Genet Cytogenet 2005; 163: 44-56.
12. Rutledge SD, Douglas TA, Nicholson JM, Vila-Casadesus M, Kantzler CL, Wangsa D, et al. Selective advantage of trisomic human cells cultured in non-standard conditions. Sci Rep 2016; 6: 22828.
13. Millet C, Ausiannikava D, Le Bihan T, Granneman S, Makovets S. C ell populations can use aneuploidy to survive telomerase insufficiency. Nat Commun 2015; 6: 8664.
14. Duncan AW, Hanlon Newell AE, Bi W, Finegold MJ, Olson SB, Beaudet AL, et al. Aneuploidy as a mechanism for stress-induced liver adaptation. J Clin Invest 2012; 122: 3307-15.
15. Ly P, Eskiocak U, Kim SB, Roig AI, Hight SK, Lulla DR, et al. Characterization of aneuploid populations with trisomy 7 and 20 derived from diploid human colonic epithelial cells. Neoplasia 2011; 13: 348-57.
16. Selmecki AM, Dulmage K, Cowen LE, Anderson JB, Berman J. Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet 2009; 5: e1000705.
17. Kwon-Chung KJ, Chang YC. Aneuploidy and drug resistance in pathogenic fungi. PLoS Pathog 2012; 8: e1003022.
18. Silk AD, Zasadil LM, Holland AJ, Vitre B, Cleveland DW, Weaver BA. Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors. Proc Natl Acad Sci U S A 2013; 110: E4134-41.
19. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 2007; 11: 25-36.
20. Duijf PH, Benezra R. The cancer biology of whole-chromosome instability. Oncogene 2013; 32: 4727-36.
21. Lynch M, Burger R, Butcher D, Gabriel W. The mutational meltdown in asexual populations. J Hered 1993; 84: 339-44.
22. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and Darwinian selection in tumours. Trends Cell Biol 1999; 9: M57-60.
23. Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, et al. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 2183-94.
24. Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 2011; 71: 3447-52.
25. Jamal-Hanjani M, A’Hern R, Birkbak NJ, Gorman P, Gronroos E, Ngang S, et al. Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: A prospective validation cohort study from the TACT trial. Ann Oncol 2015; 26: 1340-6.
26. Andor N, Graham TA, Jansen M, Xia LC, Aktipis CA, Petritsch C, et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med 2016; 22: 105-13.
27. Janssen A, Kops GJ, Medema RH. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci U S A 2009; 106: 19108-13.
28. Godek KM, Venere M, Wu Q, Mills KD, Hickey WF, Rich JN, et al. Chromosomal instability affects the tumorigenicity of glioblastoma tumor-initiating cells. Cancer Discov 2016; 6: 532-45.
29. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007; 8: 379-93.
30. Santaguida S, Tighe A, D’Alise AM, Taylor SS, Musacchio A. Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. J Cell Biol 2010; 190: 73-87.
31. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown J P, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-501.
32. Sivakumar S, Gorbsky GJ. Spatiotemporal regulation of the anaphasepromoting complex in mitosis. Nat Rev Mol Cell Biol 2015; 16: 82-94.
33. Sackton KL, Dimova N, Zeng X, Tian W, Zhang M, Sackton TB, et al. Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C. Nature 2014; 514: 646-9.
34. Manchado E, Guillamot M, de Carcer G, Eguren M, Trickey M, Garcia-Higuera I, et al. Targeting mitotic exit leads to tumor regression in vivo: Modulation by Cdk1, Mastl, and the PP2A/B55alpha,delta phosphatase. Cancer Cell 2010; 18: 641-54.
35. Zeng X, Sigoillot F, Gaur S, Choi S, PfaffKL, Oh DC, et al. Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell 2010; 18: 382-95.
36. Zhang S, Chang L, Alfieri C, Zhang Z, Yang J, Maslen S, et al. Molecular mechanism of APC/C activation by mitotic phosphorylation. Nature 2016; 533: 260-4.
37. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7.
38. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495-501.
39. L itchfield K, S ummersgill B, Y ost S, S ultana R, L abreche K, D udakia D, et al. Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. Nat Commun 2015; 6: 5973.
40. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-58.
41. Chang L, Zhang Z, Yang J, McLaughlin SH, Barford D. Atomic structure of the APC/C and its mechanism of protein ubiquitination. Nature 2015; 522: 450-4.
42. Schreiber A, Stengel F, Zhang Z, Enchev RI, Kong EH, Morris EP, et al. Structural basis for the subunit assembly of the anaphase-promoting complex. Nature 2011; 470: 227-32.
43. Chang L, Zhang Z, Yang J, McLaughlin SH, Barford D. Molecular architecture and mechanism of the anaphase-promoting complex. Nature 2014; 513: 388-93.
44. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: Application to cancer genomics. Nucleic Acids Res 2011; 39: e118.
45. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-9.
46. Koch A, Maia A, Janssen A, Medema RH. Molecular basis underlying resistance to Mps1/TTK inhibitors. Oncogene 2016; 35: 2518-28.
47. Dewhurst SM, McGranahan N, Burrell RA, Rowan AJ, Gronroos E, Endesfelder D, et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov 2014; 4: 175-85.
48. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013; 45: 1134-40.
49. Davoli T, de Lange T. The causes and consequences of polyploidy in normal development and cancer. Annu Rev Cell Dev Biol 2011; 27: 585-610.
50. Cimini D, Howell B, Maddox P, Khodjakov A, Degrassi F, Salmon ED. Merotelic kinetochore orientation is a major mechanism of aneuploidy in mitotic mammalian tissue cells. J Cell Biol 2001; 153: 517-27.
51. Bakhoum SF, Genovese G, Compton DA. Deviant kinetochore microtubule dynamics underlie chromosomal instability. Curr Biol 2009; 19: 1937-42.
52. Kwon M, Godinho SA, Chandhok NS, Ganem NJ, Azioune A, Thery M, et al. Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev 2008; 22: 2189-203.
53. Ganem NJ, Cornils H, Chiu SY, O’Rourke KP, Arnaud J, Yimlamai D, et al. Cytokinesis failure triggers hippo tumor suppressor pathway activation. Cell 2014; 158: 833-48.
54. Yang Z, Loncarek J, Khodjakov A, Rieder CL. Extra centrosomes and/or chromosomes prolong mitosis in human cells. Nat Cell Biol 2008; 10: 748-51.
55. Sansregret L, Vadnais C, Livingstone J, Kwiatkowski N, Awan A, Cadieux C, et al. Cut homeobox 1 causes chromosomal instability by promoting bipolar division after cytokinesis failure. Proc Natl Acad Sci U S A 2011; 108: 1949-54.
56. Collin P, Nashchekina O, Walker R, Pines J. The spindle assembly checkpoint works like a rheostat rather than a toggle switch. Nat Cell Biol 2013; 15: 1378-85.
57. Kabeche L, Compton DA. Cyclin A regulates kinetochore microtubules to promote faithful chromosome segregation. Nature 2013; 502: 110-3.
58. Brito DA, Rieder CL. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 2006; 16: 1194-200.
59. Kops GJ, Foltz DR, Cleveland DW. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A 2004; 101: 8699-704.
60. Janssen A, Kops GJ, Medema RH. Targeting the mitotic checkpoint to kill tumor cells. Horm Cancer 2011; 2: 113-6.
61. Burds AA, Lutum AS, Sorger PK. Generating chromosome instability through the simultaneous deletion of Mad2 and p53. Proc Natl Acad Sci U S A 2005; 102: 11296-301.
62. Zasadil LM, Andersen KA, Yeum D, Rocque GB, Wilke LG, Tevaarwerk AJ, et al. Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med 2014; 6: 229ra43.
63. Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ, et al. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res 2002; 62: 6405-9.
64. Rudolph KL, Millard M, Bosenberg MW, DePinho RA. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 2001; 28: 155-9.
65. Feldmann G, Beaty R, Hruban RH, Maitra A. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg 2007; 14: 224-32.
66. Chin K, de Solorzano CO, Knowles D, Jones A, Chou W, Rodriguez EG, et al. In situ analyses of genome instability in breast cancer. Nat Genet 2004; 36: 984-8.
67. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451: 1111-5.
68. Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 2013; 3: 68-81.
69. Welman A, Serrels A, Brunton VG, Ditzel M, Frame MC. Two-color photoactivatable probe for selective tracking of proteins and cells. J Biol Chem 2010; 285: 11607-16.
70. Murugaesu N, Wilson GA, Birkbak NJ, Watkins TB, McGranahan N, Kumar S, et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov 2015; 5: 821-31.
71. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 2014; 11: 783-4.
72. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science 2016; 351: 84-8.
73. McGranahan N, Favero F, de Bruin EC, Birkbak NJ, Szallasi Z, Swanton C. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. S ci Transl Med 2015; 7: 283ra54.
74. Moreno S, Klar A, Nurse P. Molecular genetic analysis of fission yeast Schizosaccharomyces pombe. Methods Enzymol 1991; 194: 795-823.
75. Kim DU, Hayles J, Kim D, Wood V, Park HO, Won M, et al. Analysis of a genome-wide set of gene deletions in the fission yeast Schizosaccharomyces pombe. Nat Biotechnol 2010; 28: 617-23.
76. Kamenz J, Mihaljev T, Kubis A, Legewie S, Hauf S. Robust ordering of anaphase events by adaptive thresholds and competing degradation pathways. Mol Cell 2015; 60: 446-59.
77. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-4.
78. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.